Poseida Therapeutics, Inc. – NASDAQ:PSTX

Add to watchlist

$9.54

+0.11

+1.27%

Market closed

Open in about 8 hours

+180.36%

month

+180.36%

quarter

+177.88%

year

Market Cap	920.55M
Enterprise value	195.89M

P/E	-3.05
EV/Sales	1.62
EV/EBITDA	-3773.26
Price/Sales	1.56
Price/Book	1.00
PEG ratio	-0.05
EPS	-1.19

Revenue	82.50M
EBITDA	-129.50M
Income	-107.49M
Revenue Q/Q	172.08%
Revenue Y/Y	-40.76%

Profit margin	-0.05%
Oper. margin	-0.05%
Gross margin	2.24%
EBIT margin	-0.05%
EBITDA margin	-156.98%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Poseida Therapeutics Stock Forecast

M Q Y

Last Year

$10

Potential upside: 4.82%

Analysts Price target
Financials & Ratios estimates

Poseida Therapeutics, Inc. (NASDAQ:PSTX): Profit margin
Jun 2023	20.01M	-27.45M	-137.19%
Sep 2023	9.35M	-31.77M	-339.8%
Dec 2023	24.99M	-23.99M	-95.98%
Mar 2024	28.14M	-24.27M	-86.26%

Poseida Therapeutics, Inc. (NASDAQ:PSTX): Debt to assets
Jun 2023	281215000	145.91M	51.89%
Sep 2023	302252000	178.59M	59.09%
Dec 2023	273885000	170.18M	62.14%
Mar 2024	262579999	177.98M	67.78%

Poseida Therapeutics, Inc. (NASDAQ:PSTX): Cash Flow
Jun 2023	-33.30M	43.07M	0
Sep 2023	7.88M	-47.23M	14.94M
Dec 2023	-28.74M	47.71M	94.81M
Mar 2024	-15.13M	24.00M	-43K

Poseida Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Poseida Therapeutics
Employees

Poseida Therapeutics, Inc. (NASDAQ:PSTX): Employee count
Aug 2023	343
Sep 2023	348
Oct 2023	348
Nov 2023	348
Dec 2023	327
Jan 2024	327
Feb 2024	327
Mar 2024	330
Apr 2024	330
May 2024	330
Jun 2024	335
Jul 2024	335

Poseida Therapeutics
Hedge Funds Holdings Q1 2023

29.96% -26.15%

of PSTX is owned by hedge funds

54 -34

hedge funds hold PSTX stock

21.55M -21.47M

shares is hold by hedge funds

PSTX hedge funds holdings changes

Poseida Therapeutics
Insider Trading

Poseida Therapeutics, Inc. (NASDAQ:PSTX): Insider trades (number of shares)
Period	Buy	Sel
Nov 2024	0	30000
Dec 2024	0	30000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	10 Dec 2024	GERGEN MARK J director, officer..	Common Stock	30,000	$2.78	$83,430
Sale	10 Dec 2024	GERGEN MARK J director, officer..	Common Stock	30,000	$9.46	$283,860
Option	10 Dec 2024	GERGEN MARK J director, officer..	Employee Stock Option (Right to Buy)	30,000	$2.78	$83,430
Option	26 Nov 2024	GERGEN MARK J director, officer..	Common Stock	30,000	$2.78	$83,430
Sale	26 Nov 2024	GERGEN MARK J director, officer..	Common Stock	30,000	$9.27	$278,100
Option	26 Nov 2024	GERGEN MARK J director, officer..	Employee Stock Option (Right to Buy)	30,000	$2.78	$83,430
Purchase	8 Aug 2022	MALIN LIFE SCIENCES HOLDINGS LTD 10 percent owner 10 percent owner	COMMON STOCK	2,150,000	$3.5	$7,525,000
Purchase	8 Aug 2022	OSTERTAG ERIC director, 10 perc..	Common Stock	142,857	$3.5	$500,000
Sale	3 Aug 2022	OSTERTAG ERIC director, 10 perc..	Common Stock	160,696	$3.69	$592,808
Purchase	16 Mar 2022	INGALLS KERRY D. officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	3,000	$3.98	$11,940

PSTX insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Inducible caspases and methods for use Filling date: 6 Oct 2017 Issue date: 5 Jul 2022	6 Oct 2017	5 Jul 2022
Application	Application NANOTRANSPOSON COMPOSITIONS AND METHODS OF USE Filling date: 20 Dec 2019 Issue date: 10 Feb 2022	20 Dec 2019	10 Feb 2022
Grant	Grant Utility: Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids Filling date: 28 Apr 2017 Issue date: 4 Jan 2022	28 Apr 2017	4 Jan 2022
Application	Application VCAR COMPOSITIONS AND METHODS FOR USE Filling date: 20 Dec 2018 Issue date: 13 May 2021	20 Dec 2018	13 May 2021
Application	Application COMPOSITIONS AND METHODS FOR CHIMERIC LIGAND RECEPTOR (CLR)-MEDIATED CONDITIONAL GENE EXPRESSION Filling date: 10 Sep 2018 Issue date: 6 May 2021	10 Sep 2018	6 May 2021
Grant	Grant Utility: Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles Filling date: 20 Sep 2019 Issue date: 27 Apr 2021	20 Sep 2019	27 Apr 2021
Application	Application TRANSPOSON SYSTEM AND METHODS OF USE Filling date: 31 Aug 2018 Issue date: 22 Apr 2021	31 Aug 2018	22 Apr 2021
Application	Application CARTYRIN COMPOSITIONS AND METHODS FOR USE Filling date: 7 Mar 2019 Issue date: 15 Apr 2021	7 Mar 2019	15 Apr 2021
Application	Application SITE-SPECIFIC ENZYMES AND METHODS OF USE Filling date: 16 Nov 2020 Issue date: 4 Mar 2021	16 Nov 2020	4 Mar 2021
Grant	Grant Utility: Site-specific enzymes and methods of use Filling date: 22 Jul 2019 Issue date: 24 Nov 2020	22 Jul 2019	24 Nov 2020

Poseida Therapeutics
Executives

Insider	Age	Compensation
Dr. Eric M. Ostertag (1973) Chief Executive Officer & Director	52	$858,680
Mr. Mark J. Gergen (1963) Pres, Chief Bus. Officer & Director	62	$636,490
Mr. Harry J. Leonhardt (1957) Gen. Counsel, Chief Compliance Officer & Corporation Sec.	68	$494,540

Poseida Therapeutics
Latest News

Friday, 20 December 2024
09:24	PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders	businesswire.com
Friday, 13 December 2024
10:15	Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?	zacks.com
Monday, 9 December 2024
12:00	Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting	prnewswire.com
Thursday, 28 November 2024
10:56	Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?	zacks.com
Wednesday, 27 November 2024
18:14	POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX	businesswire.com
11:00	Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet	zacks.com
10:16	Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?	zacks.com
Tuesday, 26 November 2024
20:50	SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX	prnewswire.com
13:17	Poseida shares triple on Tuesday, boosted by Roche collaboration	invezz.com
11:10	Why This Gene-Therapy Company's Stock Is Rising 228%	barrons.com
09:22	Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders	businesswire.com
09:07	Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details	benzinga.com
07:23	PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders	businesswire.com
01:29	Roche to acquire US-based Poseida Therapeutics	reuters.com
01:10	Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.	prnewswire.com
Thursday, 14 November 2024
09:00	Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline	prnewswire.com
Tuesday, 12 November 2024
13:05	Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know	zacks.com
Monday, 11 November 2024
16:05	Poseida Therapeutics to Present at Two Upcoming Investor Conferences	prnewswire.com
Thursday, 7 November 2024
18:56	Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates	zacks.com
16:05	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024	prnewswire.com
Tuesday, 5 November 2024
16:05	Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024	prnewswire.com
Thursday, 24 October 2024
08:00	Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema	prnewswire.com
Thursday, 17 October 2024
08:00	Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche	prnewswire.com
Thursday, 3 October 2024
16:30	Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024	prnewswire.com
Monday, 30 September 2024
11:47	Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement	seekingalpha.com
Friday, 27 September 2024
16:30	Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients	prnewswire.com
Monday, 16 September 2024
08:00	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma	prnewswire.com
Monday, 9 September 2024
09:16	Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024	seekingalpha.com
Thursday, 5 September 2024
09:00	Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting	prnewswire.com
Wednesday, 4 September 2024
16:05	Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma	prnewswire.com

Frequently Asked Questions (FAQ)

What's the price of Poseida Therapeutics stock today?

One share of Poseida Therapeutics stock can currently be purchased for approximately $9.54.
When is Poseida Therapeutics's next earnings date?

Unfortunately, Poseida Therapeutics's (PSTX) next earnings date is currently unknown.
Does Poseida Therapeutics pay dividends?

No, Poseida Therapeutics does not pay dividends.
How much money does Poseida Therapeutics make?

Poseida Therapeutics has a market capitalization of 920.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 50.37% to 64.7M US dollars.
What is Poseida Therapeutics's stock symbol?

Poseida Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PSTX".
What is Poseida Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Poseida Therapeutics?

Shares of Poseida Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Poseida Therapeutics's key executives?
Poseida Therapeutics's management team includes the following people:
- Dr. Eric M. Ostertag Chief Executive Officer & Director(age: 52, pay: $858,680)
- Mr. Mark J. Gergen Pres, Chief Bus. Officer & Director(age: 62, pay: $636,490)
- Mr. Harry J. Leonhardt Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 68, pay: $494,540)
How many employees does Poseida Therapeutics have?

As Jul 2024, Poseida Therapeutics employs 335 workers, which is 2% more then previous quarter.
When Poseida Therapeutics went public?

Poseida Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 10 Jul 2020.
What is Poseida Therapeutics's official website?

The official website for Poseida Therapeutics is poseida.com.
Where are Poseida Therapeutics's headquarters?

Poseida Therapeutics is headquartered at 9390 Towne Centre Drive, San Diego, CA.
How can i contact Poseida Therapeutics?

Poseida Therapeutics's mailing address is 9390 Towne Centre Drive, San Diego, CA and company can be reached via phone at 858 779 3100.
What is Poseida Therapeutics stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Poseida Therapeutics in the last 12 months, the avarage price target is $10. The average price target represents a 4.82% change from the last price of $9.54.

Poseida Therapeutics, Inc.

poseida.com

Exchange:

NASDAQ

Full time employees:

350

Industry:

Biotechnology

Sector:

Healthcare

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

858 779 3100

9390 Towne Centre Drive
San Diego, CA 92121

CIK: 0001661460
ISIN: US73730P1084
CUSIP: 73730P108